EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease

Louis Dwomoh iD, Gonzalo S Tejeda, Andrew B Tobin

Neuronal Signaling · 29.04.2022 · 6 (1)

DOI: 10.1042/ns20210004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Neuronal Signaling, online erschienen am 21.04.2022. Verfasst von Louis Dwomoh und 2 weiteren Autor:innen. Beteiligte Einrichtung: The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, Univer…. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Alzheimer’s disease (AD) remains a major cause of morbidity and mortality worldwide, and despite extensive research, only a few drugs are available for management of the disease. One strategy has been to up-regulate cholinergic neurotransmission to improve cognitive function, but this approach has dose-limiting adverse effects. To avoid these adverse effects, new drugs that target specific receptor subtypes of the cholinergic system are needed, and the M1 subtype of muscarinic acetylcholine receptor (M1-mAChR) has been shown to be a good target for this approach. By using several strategies, M1-mAChR ligands have been developed and trialled in preclinical animal models and in human studies, with varying degrees of success. This article reviews the different approaches to targeting the M1-mAChR in AD and discusses the advantages and limitations of these strategies. The factors to consider in targeting the M1-mAChR in AD are also discussed.

Schlagwörter

Stichwörter der Autor:innen

Alzheimer's diseaseacetylcholineallosteric regulationmuscarinic receptororthosteric

Autor:innen und Institutionen

  • The Centre for Translational Pharmacology, Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom.

ORCID-Profile: Louis Dwomoh

Zitieren

APA

Dwomoh, L., Tejeda, G. S., & Tobin, A. B. (2022). Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal Signaling, 6(1). https://doi.org/10.1042/ns20210004

Vancouver

Dwomoh L, Tejeda GS, Tobin AB. Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease. Neuronal Signaling. 2022;6(1). doi:10.1042/ns20210004

BibTeX
@article{Dwomoh2022,
  author = {Dwomoh, Louis and Tejeda, Gonzalo S and Tobin, Andrew B},
  title = {Targeting the M1 muscarinic acetylcholine receptor in Alzheimer’s disease},
  journal = {Neuronal Signaling},
  year = {2022},
  volume = {6},
  number = {1},
  doi = {10.1042/ns20210004}
}
Kostenlos starten →